Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Other)

Overall Status

Terminated

CT.gov ID

NCT03043989

Collaborator

Maryland Technology Development Corporation (Other)

Enrollment

Location

Arms

28.2

Actual Duration (Months)

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This clinical trial is being conducted to recommend a safe and tolerable phase 2 dose of docetaxel or cabazitaxel when combined with clarithromycin in men who have developed castrate-resistant prostate cancer.

In the castrate-resistant setting, resistance to taxane therapy inevitably develops. Men who develop resistance to taxanes have a very poor prognosis, and few treatment options.

It is believed that CYP enzymes contribute to docetaxel and cabazitaxel resistance in metastatic prostate cancer, and this resistance can be mitigated through pharmacologic CYP inhibition. In this study a potent CYP3A inhibitor, clarithromycin, will be co-administered concurrently with either docetaxel or cabazitaxel, whose systemic metabolism is dependent of CYP3A4, with the intent to overcome resistance to taxanes.

Condition or Disease	Intervention/Treatment	Phase
Prostate Cancer	Drug: Docetaxel Drug: Cabazitaxel Drug: Clarithromycin	Phase 1

Detailed Description

This is a dose-escalation study designed to determine the maximum tolerated dose of docetaxel or cabazitaxel when given in combination with clarithromycin. Eligible patients will be assigned to docetaxel or cabazitaxel, based on which drug they were previously administered prior to study entry. Enrollment to dose levels will be in a 3+3 cohort design until the maximum tolerated dose is achieved.

Docetaxel or cabazitaxel will be administered on day 1 of each (3 week) cycle for a total of 6 cycles. Subjects in both arms will be administered clarithromycin on days -1, 1 and 2 of each 3 week cycle.

Study Design

Study Type:

Interventional

Actual Enrollment :

4 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Two Independent Phase 1b Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

Actual Study Start Date :

Mar 21, 2017

Actual Primary Completion Date :

Jul 26, 2019

Actual Study Completion Date :

Jul 26, 2019

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Docetaxel and clarithromycin combination Docetaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks. Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2.	Drug: Docetaxel 6 infusions of Docetaxel with 18 doses clarithromycin Drug: Clarithromycin 18 doses of clarithromycin with either Docetaxel or Cabazitaxel
Active Comparator: Cabazitaxel and clarithromycin combination Cabazitaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks. Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2.	Drug: Cabazitaxel 6 infusions of Cabazitaxel with 18 doses clarithromycin Other Names: JEVTANA Drug: Clarithromycin 18 doses of clarithromycin with either Docetaxel or Cabazitaxel

Arm

Intervention/Treatment

Active Comparator: Docetaxel and clarithromycin combination

Docetaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks. Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2.

Drug: Docetaxel

6 infusions of Docetaxel with 18 doses clarithromycin

Drug: Clarithromycin

18 doses of clarithromycin with either Docetaxel or Cabazitaxel

Active Comparator: Cabazitaxel and clarithromycin combination

Cabazitaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks. Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2.

Drug: Cabazitaxel

6 infusions of Cabazitaxel with 18 doses clarithromycin

Other Names:

JEVTANA

Drug: Clarithromycin

18 doses of clarithromycin with either Docetaxel or Cabazitaxel

Outcome Measures

Primary Outcome Measures

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [3 years]
Escalate dose up the maximum tolerated dose achieved, and initiate this as the recommended phase 2 dose of docetaxel and of cabazitaxel when it is combined with clarithromycin. [3 years]

Secondary Outcome Measures

Compare docetaxel OR cabazitaxel exposure (maximal [Cmax] when combined with the strong CYP3A4 inhibitor clarithromycin to historic controls. [3 years]
Compare docetaxel OR cabazitaxel exposure ( total [AUC]) when combined with the strong CYP3A4 inhibitor clarithromycin to historic controls. [3 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Inclusion Criteria:

Men with metastatic castrate-resistant prostate cancer (prostate cancer progressing despite castrate levels of testosterone <50 ng/dL), using standard measures of progression defined by PCWG2
Have received at least 4 cycles of docetaxel or cabazitaxel, and less than ten, with two consecutive rising PSA values, checked at least 7 days apart. No PSA decline in last 42 day
Bone disease documented by either: a positive bone scan, CT scan, or MRI; or biopsy-proven bony metastases
Age ≥18 years
ECOG performance status ≤ 2 (Karnofsky ≥ 60%)
Have normal organ and marrow function defined as:

absolute neutrophil count ≥1,500/mcL
platelets ≥100,000/mcL
total bilirubin (within normal institutional limits)
AST/ALT ≤ 2.5 × ULN (or ≤ 1.5 x ULN in conjunction with alk phos >2.5 x ULN for Docetaxel
AST ≤ 1.5 x ULN for Cabazitaxel
creatinine clearance-no minimum for Docetaxel
creatinine clearance- ≥ 30 mL/min/1.73 m2 for Cabazitaxel

No evidence of clinical progression, in the form of increased lesions on cross-sectional imaging, or new cancer-attributable symptoms or worsening of existing symptoms
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

Patients who have residual toxicities > Grade 2 attributed to taxane therapy, except for neuropathy, who are excluded if > grade 1
Patients who are receiving any other investigational agents or have within the last 28 day.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to clarithromycin or taxanes
Patients receiving any medications or substances that are inhibitors or inducers of CYP3A4 are ineligible
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Received more than 10 cycles of docetaxel [for docetaxel cohort only] or 6 of cabazitaxel [for cabazitaxel cohort only]
Last docetaxel or cabazitaxel dose > 6 weeks prior to enrollment
Patients with a documented history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes, or taking drugs that are known to prolong the QT